Gehören Sie zu den Ersten, denen das gefällt!
A comprehensive update of the 2005 edition Examines the market for addiction pharmacotherapies currently estimated at US$2 billionThe substance dependence field is transforming into a high-growth market opportunity. Supported by the success of Pfizer's recently launched Chantix/Champix, which is on track for blockbuster status in the smoking cessation sector, pharmacotherapies in development for alcohol, narcotic, and nicotine dependencies are poised to radically change the addiction treatment landscape in this difficult-to-treat patient population.The report estimates that the current market for addiction disorders is valued at US$3.2 billion and this is forecast to increase 19% to US$3.8 billion by 2016.The World Market for Addiction Disorders, 2009 2016: Future Therapies for Substance Dependence and Impulse Control, will introduce the reader a specialty pharmaceutical market which is positioned for high-growth based on analysis of marketed and pipeline drugs, company activities, and addiction disorder demographics.Therapy area forecasting and illustrative comparative sales data is presented to gain insight into leading products with sales estimates to 2016.Objectives of ReportThe objectives of this 80 page report are to provide an in-depth analysis of the global addiction pharmacotherapeutic market. Included in this study are analyses of key therapy areas, R&D programs, and innovating companies and products. The reader will benefit from market forecasts, pooled knowledge of recent industrial activities and events, and from analytical discourse, which is intended to stimulate growth and create new market opportunities.Report Highlights Include:' The current market for addiction disorders is valued at US$3.2 billion, up from US$2 billion in 2005' Critical analysis of alcohol, cocaine, opiate, and nicotine addictions' Review of epidemiological, aetiological, and demographic data for addiction disorders' Analysis of over 10 key marketed products and inclusion of 34 R&D candidates identified in preclinical to clinical stages of development for addiction disorders' Sales estimates (US$) to 2012 for major therapy areas' Strategic insights for life-cycle optimization and product development' Critical evaluation of leading addiction pharmacotherapies' Emerging markets identified and sector analysis' Trend analysis of industry events and activities over past 2 years' Detailed R&D themes and clusters by addiction area' Data generation on sector and market values between 2004 and 2012 and therapy forecasts by 2020 (US$)' High revenue-yielding prospects identified with projected sales estimations' R&D pipeline positioning for novel candidates' Market insights for product development and drug promotionWhat you can learn from this report:' Which addiction therapies are the current and potential future market leaders' How companies are reformulating products for addiction indications' Which premarket addiction pharmacotherapies are identified as high-value products' Which companies are developing drugs for addiction disorders' Sales predictions to 2016 for addiction pharmacotherapies' What the likely impact of pipeline products will be on value growth of the addiction market over the 10 years' Which addiction subsectors could be niche market opportunities' What the future outlook holds for addiction pharmacotherapies' Insight into R&D trends for alcohol, cocaine, opiate, and nicotine addictions' Which molecules and compounds are main R&D clusters for dependency disorders' Which of the pipeline candidates are top prospects in the addiction market over the next decade and to 2025Report Contains:' Detailed survey and analysis of the current and future global addiction disorder market' Comprehensive update on key marketed products indicated for alcohol, narcotic, and nicotine dependency disorders' Review of epidemiological, demographic, aetiological, and therapeutic data associated with addiction disorders' Market analysis and insight of key